NMTR - 9 Meters Biopharma slumps continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma ([[NMTR]]) announces a collaboration with the European Biomedical Research Institute of Salerno (or EBRIS), to advance to a study in order to evaluate the safety and tolerability of larazotide when delivered to lung tissue in healthy volunteers. Larazotide, a first-in-class tight junction modulator, is hypothesized to act on lung endothelial cells.It has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patients.Phase 1 study expected to begin in 2021."We are delighted to collaborate with the 9 Meters team in order to secure larazotide and investigate its safety and tolerability in a formulation suitable for lung delivery, which will ultimately advance our goal of testing this novel tight junction modulator in patients with SARS-CoV-2 infection," commented Alessio Fasano, M.D., president of EBRIS and Director, Mucosal Immunology and Biology Research Center; and Associate Chief for Basic, Clinical and

For further details see:

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications